1,160 reports of this reaction
2.0% of all PROPOFOL reports
#9 most reported adverse reaction
TACHYCARDIA is the #9 most commonly reported adverse reaction for PROPOFOL, manufactured by Fresenius Kabi USA, LLC. There are 1,160 FDA adverse event reports linking PROPOFOL to TACHYCARDIA. This represents approximately 2.0% of all 57,130 adverse event reports for this drug.
PROPOFOL has an overall safety score of 95 out of 100. Patients taking PROPOFOL who experience tachycardia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
TACHYCARDIA is a less commonly reported adverse event for PROPOFOL, but still significant enough to appear in the safety profile.
In addition to tachycardia, the following adverse reactions have been reported for PROPOFOL:
The following drugs have also been linked to tachycardia in FDA adverse event reports:
TACHYCARDIA has been reported as an adverse event in 1,160 FDA reports for PROPOFOL. This does not prove causation, but indicates an association observed in post-market surveillance data.
TACHYCARDIA accounts for approximately 2.0% of all adverse event reports for PROPOFOL, making it a notable side effect.
If you experience tachycardia while taking PROPOFOL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.